How to buy Neuren Pharmaceuticals (NEU) shares
Learn how to easily invest in Neuren Pharmaceuticals shares.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Neuren Pharmaceuticals Limited is a biotechnology business based in Australia. Neuren Pharmaceuticals shares (NEU) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Neuren Pharmaceuticals has a trailing 12-month revenue of around $717,000. If you're looking to buy shares, check out the steps below.
How to buy shares in Neuren Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Neuren Pharmaceuticals . Find the share by name or ticker symbol: NEU. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Neuren Pharmaceuticals reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Neuren Pharmaceuticals . Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- Neuren Pharmaceuticals key stats
- Compare share trading platforms
- Is Neuren Pharmaceuticals stock a buy or sell?
- Neuren Pharmaceuticals performance over time
- Neuren Pharmaceuticals 's financials
- How volatile are Neuren Pharmaceuticals shares?
- Does Neuren Pharmaceuticals pay a dividend?
- Have Neuren Pharmaceuticals shares ever split?
- Other common questions
Neuren Pharmaceuticals stock price (ASX:NEU)Use our graph to track the performance of NEU stocks over time.
Neuren Pharmaceuticals shares at a glance
|52-week range||$0.995 - $2.5|
|50-day moving average||$2.1405|
|200-day moving average||$1.5857|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.109|
Compare share trading platforms
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
Is it a good time to buy Neuren Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Neuren Pharmaceuticals price performance over time
|1 week (2021-09-17)||0.48%|
|1 month (2021-08-25)||-6.70%|
|3 months (2021-06-25)||41.22%|
|6 months (2021-03-25)||51.45%|
|1 year (2020-09-25)||81.74%|
|2 years (2019-09-25)||4.50%|
|3 years (2018-09-25)||64.57%|
|5 years (2016-09-23)||-89.75%|
Is Neuren Pharmaceuticals under- or over-valued?
Valuing Neuren Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neuren Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neuren Pharmaceuticals 's EBITDA
Neuren Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.8 million (£980,123).
The EBITDA is a measure of a Neuren Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.
Neuren Pharmaceuticals financials
|Gross profit TTM||$-7,046,000|
|Return on assets TTM||-50.94%|
|Return on equity TTM||-96.34%|
|Market capitalisation||$266.2 million|
TTM: trailing 12 months
Neuren Pharmaceuticals share dividends
We're not expecting Neuren Pharmaceuticals to pay a dividend over the next 12 months.
Have Neuren Pharmaceuticals 's shares ever split?
Neuren Pharmaceuticals 's shares were split on a 1:20 basis on 20 November 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neuren Pharmaceuticals shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Neuren Pharmaceuticals shares which in turn could have impacted Neuren Pharmaceuticals 's share price.
Neuren Pharmaceuticals share price volatility
Over the last 12 months, Neuren Pharmaceuticals 's shares have ranged in value from as little as $0.995 up to $2.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Neuren Pharmaceuticals 's is 1.3438. This would suggest that Neuren Pharmaceuticals 's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Neuren Pharmaceuticals overview
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Stocks similar to Neuren Pharmaceuticals
Neuren Pharmaceuticals in the news
Frequently asked questions
More guides on Finder
How to invest in the Cosmos Exploration IPO
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
What is behind the bounce in the Zip Co share price?
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Why the AGL share price has rebounded today
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
How to invest in the Dundas Minerals IPO
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
How to invest in the Kalgoorlie Gold Mining IPO
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
The best iron ore stocks on the ASX (2021)
We look at some of the biggest and best performing iron ore stocks in Australia.
Why are the CBA and WBC share prices stumbling today?
Shares in the major banks have risen more than 50% in the last 12 months.
How to buy Evergrande shares from Australia
Steps to owning and managing China Evergrande Group shares from Australia.
How to invest in the Hamelin Gold IPO
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
How to invest in the Lykos Metals IPO
Everything we know about the Lykos Metals IPO, plus information on how to buy in.
Ask an Expert